ZYME

#1969
Zymeworks Inc.
26.9800 USD
+3.10%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
26.9800
26.9800
Intervallo Annuale
16.0034
28.4900
Variazione giornaliera
+3.10%
Variazione Mensile
+16.44%
Variazione di 6 mesi
+52.09%
Variazione Annuale
+52.09%
Chiusura Precedente
26.1700
Apertura
26.9800
Bid
Ask
Minimo
26.9800
High
26.9800
Volume
148
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
Conto economico Bilancio Liquidità
Valore Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Zymeworks Inc

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

Notizie